IQVIA sees U.S. MASH diagnostics topping USD 1.5 billion by 2033
Genfit flagged U.S. peak sales above USD 1.5 billion by 2033 for MASH diagnostics using its NIS technology, citing IQVIA.
Annual U.S. testing volume is projected above 7 million tests by 2033, targeting 86 million monitored patients with MASLD-related risk factors.
The adoption outlook is tied to expanding reimbursement, guideline inclusion, rising disease awareness, and wider use beyond specialists into primary care.
Medicare reimbursement for Labcorp’s NASHnext test became effective in August 2026 under the Clinical Laboratory Fee Schedule, supporting uptake.
Diagnostics demand is expected to accelerate from 2028 as additional MASH therapies expand screening and monitoring needs.
XLV•
